当前位置: 首页 >> 检索结果
1001. Botulinum toxin injection versus lateral internal sphincterotomy in the treatment of chronic anal fissure: a non-randomized controlled trial.
作者: Adnan Giral.;Kemal Memisoglu.;Yücel Gültekin.;Neşe Imeryüz.;Cem Kalayci.;Nefise B Ulusoy.;Nurdan Tözün.
来源: BMC Gastroenterol. 2004年4卷7页
Although lateral internal sphincterotomy is the gold-standard treatment for chronic anal fissure, intrasphincteric injection of botulinum toxin seems to be a reliable new option. The aim of this non-randomized study is to compare the effect of lateral internal sphincterotomy and botulinum toxin injection treatments on the outcome and reduction of anal sphincter pressures in patients with chronic anal fissure.
1002. Effect of four-day psyllium supplementation on bowel preparation for colonoscopy:A prospective double blind randomized trial [ISRCTN76623768].
Patients with new onset constipation or presumed hemorrhoid bleeding frequently require the use of both fiber supplements and diagnostic colonoscopy. We sought to determine whether preliminary fiber supplementation would alter the tolerability or efficacy of a standard bowel preparation for colonoscopy
1003. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis.
作者: Carmen Zafra.;Juan G Abraldes.;Juan Turnes.;Annalisa Berzigotti.;Mercedes Fernández.;Juan C Garca-Pagán.;Juan Rodés.;Jaime Bosch.
来源: Gastroenterology. 2004年126卷3期749-55页
In cirrhosis, an insufficient release of nitric oxide contributes to increased hepatic resistance and portal pressure and enhances the postprandial increase in portal pressure. We hypothesized that simvastatin, which enhances Akt-dependent endothelial nitric oxide synthase phosphorylation, may increase hepatic nitric oxide release and decrease hepatic resistance in patients with cirrhosis and portal hypertension.
1004. The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D-aspartate receptor.
作者: Robert Paul Willert.;Clifford J Woolf.;Anthony Robert Hobson.;Claire Delaney.;David G Thompson.;Qasim Aziz.
来源: Gastroenterology. 2004年126卷3期683-92页
Visceral hypersensitivity is a common feature of functional gastrointestinal disorders. One speculated mechanism is an activity-dependent increase in spinal cord neuronal excitability (central sensitization), which is dependent on activation of the N-methyl-D-aspartate (NMDA) receptor. Our aims were to determine whether the development and maintenance of human visceral hypersensitivity is NMDA receptor mediated.
1005. Outcome of patients with obscure gastrointestinal bleeding after capsule endoscopy: report of 100 consecutive cases.
作者: Marco Pennazio.;Renato Santucci.;Emanuele Rondonotti.;Carla Abbiati.;Gizela Beccari.;Francesco P Rossini.;Roberto De Franchis.
来源: Gastroenterology. 2004年126卷3期643-53页
Capsule endoscopy (CE) is a promising diagnostic tool for the study of patients with obscure gastrointestinal bleeding. However, the diagnostic yield of this technique has not been adequately studied. We evaluated sensitivity and specificity of CE and the outcome after CE in patients with obscure gastrointestinal bleeding.
1006. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study.
作者: Christophe Bureau.;Juan Carlos Garcia-Pagan.;Philippe Otal.;Gilles Pomier-Layrargues.;Valérie Chabbert.;Carlos Cortez.;Pierre Perreault.;Jean Marie Péron.;Juan G Abraldes.;Louis Bouchard.;José Ignacio Bilbao.;Jaume Bosch.;Hervé Rousseau.;Jean Pierre Vinel.
来源: Gastroenterology. 2004年126卷2期469-75页
A 50% dysfunction rate at 1 year is one of the main drawbacks of the transjugular intrahepatic portosystemic shunt procedure. Preliminary experimental and clinical studies suggest that the use of stents covered with polytetrafluoroethylene could tremendously decrease this risk.
1007. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.
作者: Francis M Giardiello.;Robert A Casero.;Stanley R Hamilton.;Linda M Hylind.;Jill D Trimbath.;Deborah E Geiman.;Katharine R Judge.;Walter Hubbard.;G Johan A Offerhaus.;Vincent W Yang.
来源: Gastroenterology. 2004年126卷2期425-31页
Familial adenomatous polyposis because of germline mutation of the adenomatous polyposis coli gene is characterized by development of colorectal adenomas and, ultimately, colorectal cancer. The usefulness of colorectal mucosal compounds to predict the effect on adenoma development of primary chemoprevention with the nonsteroidal anti-inflammatory drug sulindac was evaluated.
1008. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
作者: Paul Rutgeerts.;Brian G Feagan.;Gary R Lichtenstein.;Lloyd F Mayer.;Stefan Schreiber.;Jean Frederic Colombel.;Daniel Rachmilewitz.;Douglas C Wolf.;Allan Olson.;Weihang Bao.;Stephen B Hanauer.
来源: Gastroenterology. 2004年126卷2期402-13页
This analysis of Crohn's disease patients treated with infliximab in ACCENT I compared episodic and scheduled treatment strategies under conditions that simulate clinical practice.
1009. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.
作者: George K K Lau.;Harry H Y Yiu.;Daniel Y T Fong.;Hoi-Ching Cheng.;Wing-Yan Au.;Lydia S F Lai.;Micheal Cheung.;Hai-Ying Zhang.;Albert Lie.;Roger Ngan.;Raymond Liang.
来源: Gastroenterology. 2003年125卷6期1742-9页
Hepatitis B virus reactivation is a serious cause of morbidity and mortality in hepatitis B surface antigen-positive patients treated with chemotherapy. We compared the efficacy of early and deferred preemptive lamivudine therapy in reducing the incidence of hepatitis due to hepatitis B virus reactivation in hepatitis B surface antigen-positive lymphoma patients treated with chemotherapy.
1010. Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
作者: Anna S F Lok.;Ching-Lung Lai.;Nancy Leung.;Guang-Bi Yao.;Zhen-Yu Cui.;Eugene R Schiff.;Jules L Dienstag.;E Jenny Heathcote.;Nancy R Little.;Dorothea A Griffiths.;Stephen D Gardner.;Mary Castiglia.
来源: Gastroenterology. 2003年125卷6期1714-22页
Data on the long-term safety of lamivudine are limited. The aim of this analysis was to determine the incidence of hepatitis flares, hepatic decompensation, and liver-disease-related (LDR) serious adverse events (SAE) during long-term lamivudine treatment.
1011. Unsedated ultrathin EGD is well accepted when compared with conventional sedated EGD: a multicenter randomized trial.
作者: Ruel T Garcia.;John P Cello.;Mindie H Nguyen.;Stanley J Rogers.;Alex Rodas.;Huy N Trinh.;Neil H Stollman.;Gail Schlueck.;Kenneth R McQuaid.
来源: Gastroenterology. 2003年125卷6期1606-12页
In the United States, upper gastrointestinal endoscopy is usually performed using intravenous sedation. Sedation increases the rate of both complications and costs of endoscopy. Unsedated esophagogastroduodenoscopy (EGD) using conventional 8-11-mm endoscopes is an alternative to sedated endoscopy but is generally perceived as unacceptable to many American patients. Unsedated EGD using ultrathin 5-6-mm endoscopes is better tolerated. A randomized trial comparing unsedated ultrathin EGD (UT-EGD) with sedated conventional EGD (C-EGD) in a diverse American population is needed.
1012. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
作者: Marion G Peters.;H w Hann Hw.;Paul Martin.;E Jenny Heathcote.;P Buggisch.;R Rubin.;M Bourliere.;K Kowdley.;C Trepo.;D f Gray Df.;M Sullivan.;K Kleber.;R Ebrahimi.;S Xiong.;Carol L Brosgart.
来源: Gastroenterology. 2004年126卷1期91-101页
Adefovir dipivoxil possesses potent in vitro and in vivo antiviral activity in wild-type hepatitis B. This study assessed the safety and efficacy of adefovir dipivoxil alone and in combination with lamivudine compared with ongoing lamivudine therapy in patients with chronic hepatitis B with compensated liver disease and lamivudine-resistant hepatitis B virus (HBV).
1013. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.
作者: Robert Perrillo.;Hie-Won Hann.;David Mutimer.;Bernard Willems.;Nancy Leung.;William M Lee.;Alison Moorat.;Stephen Gardner.;Mary Woessner.;Eric Bourne.;Carol L Brosgart.;Eugene Schiff.
来源: Gastroenterology. 2004年126卷1期81-90页
Prolonged lamivudine therapy is associated with treatment-resistant YMDD mutant hepatitis B virus (HBV). We evaluated the efficacy and safety of adding adefovir dipivoxil to lamivudine in 135 patients with chronic hepatitis B (CHB) and YMDD mutant HBV.
1014. Mechanoreceptors of the proximal stomach: Role in triggering transient lower esophageal sphincter relaxation.
作者: Roberto Penagini.;Stefania Carmagnola.;Paolo Cantù.;Mariangela Allocca.;Paolo A Bianchi.
来源: Gastroenterology. 2004年126卷1期49-56页
The role of fundic tension and stretch mechanoreceptors in triggering transient lower esophageal sphincter (LES) relaxation is still unknown. This information would be useful for the development of effective pharmacologic strategies. To elucidate this topic, gastric contractile activity was modified during isovolumetric gastric distention at 2 different volumes.
1015. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study.
作者: Marianne E J Ortner.;Karel Caca.;Frieder Berr.;Jochen Liebetruth.;Ulrich Mansmann.;Dominik Huster.;Winfried Voderholzer.;Guido Schachschal.;Joachim Mössner.;Herbert Lochs.
来源: Gastroenterology. 2003年125卷5期1355-63页
In nonrandomized trials, photodynamic therapy (PDT) had a promising effect on nonresectable cholangiocarcinoma (NCC). This prospective, open-label, randomized, multicenter study with a group sequential design compared PDT in addition to stenting (group A) with stenting alone (group B) in patients with NCC.
1016. Randomized controlled trial of biofeedback for fecal incontinence.
作者: Christine Norton.;Sonya Chelvanayagam.;Jenifer Wilson-Barnett.;Sally Redfern.;Michael A Kamm.
来源: Gastroenterology. 2003年125卷5期1320-9页
Behavioral treatment (biofeedback) has been reported to improve fecal incontinence but has not been compared with standard care.
1017. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.
作者: Gert Van Assche.;Geert D'Haens.;Maja Noman.;Séverine Vermeire.;Martin Hiele.;Katrien Asnong.;Joris Arts.;Andre D'Hoore.;Freddy Penninckx.;Paul Rutgeerts.
来源: Gastroenterology. 2003年125卷4期1025-31页
Cyclosporine A is highly effective in severe attacks of ulcerative colitis (UC) but is associated with important adverse effects that are mainly dose dependent. Our single center, randomized, double-blind, controlled trial aimed to evaluate the additional clinical benefit of 4 mg/kg over 2 mg/kg IV cyclosporine in the acute treatment of severe UC.
1018. Esophagogastric junction opening during relaxation distinguishes nonhernia reflux patients, hernia patients, and normal subjects.
作者: John E Pandolfino.;Guoxiang Shi.;Brian Trueworthy.;Peter J Kahrilas.
来源: Gastroenterology. 2003年125卷4期1018-24页
Flow across the esophagogastric junction (EGJ) is strongly related to opening dimensions. This study aimed to determine whether opening of the relaxed EGJ was altered in patients with gastroesophageal reflux disease (GERD).
1019. The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases.
作者: Stephen W Fenwick.;Giles J Toogood.;J Peter A Lodge.;Mark A Hull.
来源: Gastroenterology. 2003年125卷3期716-29页
Cyclooxygenase-2 (COX-2) is a potential target for chemotherapy of colorectal cancer (CRC). We tested the antineoplastic activity of the selective COX-2 inhibitor rofecoxib on human CRC liver metastases by measuring surrogate markers of tumor growth and angiogenesis in a randomized, double-blind, placebo-controlled trial.
1020. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial.
作者: Douglas A Corley.;Philip Katz.;John M Wo.;Andreas Stefan.;Marco Patti.;Richard Rothstein.;Steven Edmundowicz.;Michael Kline.;Rodney Mason.;M Michael Wolfe.
来源: Gastroenterology. 2003年125卷3期668-76页
Gastroesophageal reflux disease is a prevalent disorder that often requires long-term medical therapy or surgery. The United States Food and Drug Administration recently cleared new endoluminal gastroesophageal reflux disease treatments; however, no controlled trials exist.
|